Earnings per share for the last twelve months: Eagle Pharma (EGRX)

EGRX (Eagle Pharma) - company brandmark

Eagle Pharmaceuticals effectively scales its business through fixed R&D costs and the utilization of partner capacities. On GURU.Markets, the TTM net income per share clearly confirms this model, where 0.85 captures the current value of the indicator. Stable sales in oncology centers ensure profitability, while the company's status as a trusted developer of critical formulations strengthens its market position.

EGRX (Eagle Pharma) Net earnings per share for the last 12 months history from 07/04/2022 to 10/12/2024

Analytical breakdowns for Eagle Pharma (EGRX)

- company stock exchange capitalization indicators:
Basic company analysis:Eagle Pharmaceuticals, Inc. (EGRX)
Mass-produced product of Eagle Pharmaceuticals Inc.

The indicator is calculated by dividing the total annual net income by the total number of common shares. This metric measures the actual efficiency of capital generation, excluding the impact of issuance factors. For Eagle Pharmaceuticals (EGRX), profit growth is driven by the introduction of innovative liquid drug formulations within a mature market. The daily price action of earnings per share over the last 12 months confirms the resilience of the business model as the customer base expands.